The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | BCMA-targeting therapies in myeloma
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, of the University College London Hospitals, London, UK, highlights B-cell maturation antigen (BCMA) targeting therapies in multiple myeloma including belantamab mafodotin, a BCMA targeting antibody-drug conjugate, as well as ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel), two different BCMA CAR-T cell therapies. Dr Popat also highlights novel BiTEs presented at EHA 2020 such as teclistamab, a BCMA x CD3 bispecific antibody investigated in a Phase I dose-escalation study. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
